CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Giulio Draetta: Tremendously proud of Tina Cascone for her

Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation

MD Anderson Cancer Center on X: “These findings add to evidence

Science At BMS on X: At #ESMO23, hear the results of

The Cancer News - Authoritative Resource for Everything About

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Neoadjuvant nivolumab with or without platinum-doublet

主席专场四大临床研究数据披露，改写多个癌种治疗新格局｜ESMO重磅速递

Dipesh Uprety MD FACP on X: CheckMate-77T #ESMO23 @ESMO

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

CheckMate-77T: Perioperative nivolumab benefit for NSCLC - ecancer

The Era of Neoadjuvant Immunotherapy in Resectable Non–Small Cell

肺癌围术期研究CheckMate-77T报捷，欧狄沃用于可切除肺癌再证疗效医药